![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/20372503-691765001-0b0b7a5a-a1d1-11e6-9041-cbc40d61c8f5-100x53.jpeg)
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief …